July 20, 2016
Rhythm Pharmaceuticals
Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity
July 19, 2016
Fulcrum Therapeutics
Third Rock Ventures Launches Fulcrum Therapeutics with $55 Million Series A Investment
July 19, 2016
Jounce Therapeutics
Jounce Therapeutics Announces Major Strategic Collaboration with Celgene Corporation to Develop Next-generation Immuno-oncology Therapies for Patients with Cancer
July 19, 2016
Sage Therapeutics
Sage Appoints Geno Germano to Company\'s Board of Directors
July 19, 2016
Zafgen
Zafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061